Trading Report: Today, Trupanion Inc (TRUP) Lowered by The Zacks Investment Research to Hold

Today, Trupanion Inc (TRUP) Lowered by The Zacks Investment Research to Hold

Trupanion Inc (NYSE:TRUP) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Friday.

According to Zacks, “Trupanion, Inc. operates as a direct-to-consumer monthly subscription service provider of a medical insurance plan for cats and dogs. It operates primarily in Canada, Puerto Rico, and the United States. The Company serves pet owners and veterinarians. Trupanion, Inc. is headquartered in Seattle, Washington. “

TRUP has been the topic of several other reports. RBC Capital Markets set a $18.00 price objective on Trupanion and gave the company a “buy” rating in a report on Tuesday, September 20th. Canaccord Genuity reaffirmed a “buy” rating and issued a $19.00 price target on shares of Trupanion in a research note on Thursday, August 4th. Finally, Stifel Nicolaus lifted their price target on Trupanion from $17.00 to $20.00 and gave the stock a “buy” rating in a research note on Wednesday, August 3rd. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $16.00.

Shares of Trupanion (NYSE:TRUP) opened at 16.75 on Friday. Trupanion has a 1-year low of $7.61 and a 1-year high of $17.68. The firm has a 50-day moving average price of $16.12 and a 200-day moving average price of $15.19. The stock’s market cap is $489.99 million.

Trupanion (NYSE:TRUP) last issued its quarterly earnings data on Tuesday, November 1st. The company reported ($0.06) EPS for the quarter, meeting the consensus estimate of ($0.06). The business earned $48.40 million during the quarter, compared to analyst estimates of $48.17 million. During the same period in the previous year, the business posted ($0.17) earnings per share. The firm’s revenue for the quarter was up 27.7% on a year-over-year basis. Equities analysts forecast that Trupanion will post ($0.23) EPS for the current year.

In other Trupanion news, Director Howard E. Rubin sold 75,000 shares of the business’s stock in a transaction on Monday, October 3rd. The stock was sold at an average price of $16.56, for a total transaction of $1,242,000.00. Following the transaction, the director now owns 100,000 shares of the company’s stock, valued at $1,656,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Darryl Rawlings sold 3,500 shares of the business’s stock in a transaction on Thursday, October 20th. The stock was sold at an average price of $16.15, for a total value of $56,525.00. Following the transaction, the insider now directly owns 1,523,005 shares in the company, valued at approximately $24,596,530.75. The disclosure for this sale can be found here.

A number of institutional investors have recently added to or reduced their stakes in the company. BlackRock Advisors LLC increased its stake in Trupanion by 88.0% in the third quarter. BlackRock Advisors LLC now owns 8,616 shares of the company’s stock worth $146,000 after buying an additional 4,032 shares in the last quarter. AQR Capital Management LLC acquired a new stake in Trupanion during the second quarter worth approximately $146,000. The Manufacturers Life Insurance Company acquired a new stake in Trupanion during the third quarter worth approximately $194,000. Metropolitan Life Insurance Co. NY acquired a new stake in Trupanion during the second quarter worth approximately $160,000. Finally, A.R.T. Advisors LLC acquired a new stake in Trupanion during the second quarter worth approximately $166,000.

About Trupanion

Trupanion, Inc provides a medical insurance plan for cats and dogs across the United States, Canada and Puerto Rico. The Company operates through two segments: subscription business and other business. The subscription business segment includes monthly subscriptions related to the Company’s medical plan, which are marketed directly to consumers.

Related posts

Leave a Comment